Long-term survival following upgrade compared with de novo cardiac resynchronization therapy implantation: a single-centre, high-volume experience.

Walter Richard Schwertner Anett BehonEperke Dóra MerkelMarton TokodiAttila KovácsEndre ZimaIstván OsztheimerLevente MolnárÁkos KirályRoland PappLászló GellérLuca KuthiBoglárka VeresAnnamária KosztinBéla Merkely

Published in: Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology (2021)

In our retrospective analysis, upgrade patients had a higher risk of all-cause mortality than de novo patients, which might be attributable to their more significant comorbidity burden. The occurrence of lead dysfunction and pocket infections was more frequent in the upgrade group.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
cardiac resynchronization therapy
prognostic factors
heart failure
risk assessment
left ventricular
patient reported outcomes
patient reported
atrial fibrillation